Literature DB >> 1417372

Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis. A review and suggestions.

J M Greene1, R N Winickoff.   

Abstract

Salicylates and nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the treatment of painful disorders. This article reviews the efficacy, side effects, and costs of these agents and proposes a practical approach to using them in a cost-effective manner. Although there may be some differences in efficacy among available drugs, these do not appear sufficient to justify using the more expensive agents in most cases. Adverse effects, especially gastrointestinal (GI), add to the cost of using these drugs. Aspirin and all nonsalicylate NSAIDs share a risk of causing gastric ulcer, upper GI bleeding, and GI perforation. Prostaglandin inhibition by these agents may lead to reduced glomerular filtration rate and renal failure. There may be modest differences in GI and renal risks with the different agents, but these are minimal. Prophylaxis against gastric ulceration with anti-ulcer drugs has been recommended, and one agent, misoprostol, is approved for use in the United States for this purpose. Whether use of prophylaxis will increase or decrease the costs associated with NSAID therapy remains to be determined. Nonacetylated salicylates may cause less GI adverse effects and may be somewhat "renal sparing." Strategies that would reduce the cost of care for painful musculoskeletal disorders without compromising quality of care include using acetaminophen instead of an NSAID for noninflammatory disorders, trying nonacetylated salicylates as less expensive and safer alternatives to NSAIDs, using one agent at a time, allowing sufficient time to evaluate the therapeutic effect before changing agents, returning to the least expensive and/or safest drug if a trial of several in succession fails to find one that is clearly better, and reserving prophylactic use of antiulcer agents for patients who are at especially high risk and for whom anti-inflammatory effects are clearly needed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1417372

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

Review 1.  Systematic review of the cost effectiveness of prophylactic treatments in the prevention of gastropathy in patients with rheumatoid arthritis or osteoarthritis taking non-steroidal anti-inflammatory drugs.

Authors:  H E van Dieten; I B Korthals-de Bos; M W van Tulder; W F Lems; B A Dijkmans; M Boers
Journal:  Ann Rheum Dis       Date:  2000-10       Impact factor: 19.103

Review 2.  Pharmacoeconomics of chronic nonmalignant pain.

Authors:  M J Zagari; P D Mazonson; W C Longton
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 3.  NSAIDs and the elderly. Toxicity and economic implications.

Authors:  A C Phillips; R P Polisson; L S Simon
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

4.  Inhibition of COX1/2 alters the host response and reduces ECM scaffold mediated constructive tissue remodeling in a rodent model of skeletal muscle injury.

Authors:  Christopher L Dearth; Peter F Slivka; Scott A Stewart; Timothy J Keane; Justin K Tay; Ricardo Londono; Qingnian Goh; Francis X Pizza; Stephen F Badylak
Journal:  Acta Biomater       Date:  2015-12-02       Impact factor: 8.947

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.